? DEVELOPMENTAL FUNDS The OSUCCC has provided seed funding for faculty recruitment and shared resource development. During the current grant cycle, 17 faculty were recruited, 8 of which were at the associate or full professor level. These faculty were strategically recruited to all 5 research programs and most focus on research relevant to the OSUCCC catchment area. They span 5 different colleges, 10 different departments across the colleges, and include Nationwide Children?s Hospital. Developmental funds used to support these faculty was $1,937,467. These investigators received $32,567,789 in NCI funding and $35,813,889 total peer-review funding, yielding a return on investment from CCSG developmental funds of 18:1. For the current funding cycle, we also established two developing shared resources (permitted under the prior CCSG guidelines), which were the Solid Tumor Translational developing Shared Resource (STTdSR) and the Veterinary Clinical Research Support Developing Shared Resource (VCRSdSR). The STTdSR has matured and is now called the Clinical-Translational Science Shared Resource (CTSSR) to reflect more broad use to include investigators focused on hematological malignancies and population science, in addition to those doing solid tumor research. Funding for this shared resource is requested in the current CCSG application. The VCRSdSR remains a developing shared resource; however, this will be supported from institutional funds and no CCSG funding is requested.
The Specific Aims for Developmental Funds are: 1) to expand innovative and high-impact science focused on our four strategic priorities: immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship; 2) to identify and recruit senior, midlevel and early career faculty whose scientific expertise targets relevant needs in the OSUCCC strategic plan and catchment area (CA); and, 3) to use a robust evaluation process and provide seed funding for research projects that are inter-programmatic collaborations and/or are community focused, leading to NCI funding at the R01- or P01-equivalent level. To achieve these aims, for the current application, funds are being requested for the recruitment of investigators (n=18) matched to the OSUCCC research priorities and programmatic and catchment area needs. The OSUCCC also is requesting funding to leverage our highly successful Pelotonia-funded pilot awards program, called the Intramural Research Program. This is an externally peer reviewed mechanism that prioritizes projects for funding based on scientific merit and research focused on our catchment area, with additional consideration for early stage investigators. CSSG pilot funding will specifically target synergistic projects spanning two or more research programs representing inter-programmatic collaborations, and/or or projects developing community partnerships (funding for new shared resources are requested in the Shared Resource Management budget). Developmental funds and the CCSG review process are a critical way that our university evaluates the impact of the OSUCCC and allows us to substantially leverage our ongoing and substantial institutional commitments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089999
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Neff, Robert; Rush, Craig M; Smith, Blair et al. (2018) Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. Int J Cancer 143:2955-2961
Comiskey Jr, D F; Jacob, A G; Sanford, B L et al. (2018) A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene 37:95-106
Dietrich, Sascha; Ole?, Ma?gorzata; Lu, Junyan et al. (2018) Drug-perturbation-based stratification of blood cancer. J Clin Invest 128:427-445
Chen, Zhong; Wu, Dayong; Thomas-Ahner, Jennifer M et al. (2018) Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci U S A 115:6810-6815
Moshiri, Farzaneh; Salvi, Alessandro; Gramantieri, Laura et al. (2018) Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 9:15350-15364
Petrov, Brawnie; Aldoori, Ayat; James, Cindy et al. (2018) Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Transl Psychiatry 8:61
Senaras, Caglar; Niazi, Muhammad Khalid Khan; Sahiner, Berkman et al. (2018) Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images. PLoS One 13:e0196846
Kovac, Rachel L; Ballash, Gregory; Fenger, Joelle et al. (2018) Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. J Vet Intern Med 32:2061-2068
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Yi, Long; Chen, Luxi; Guo, Xiaofeng et al. (2018) A Synthetic Disaccharide Derivative of Diphyllin, TAARD, Activates Human Natural Killer Cells to Secrete Interferon-Gamma via Toll-Like Receptor-Mediated NF-?B and STAT3 Signaling Pathways. Front Immunol 9:1509

Showing the most recent 10 out of 2602 publications